PET-Associated Incidental Neoplasms of the Thyroid

Journal of the American College of Surgeons

Volumn 207, Issue 2, 2008, Pages 259-264

  Katz, Steven C ^a   Shaha, Ashok ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; GLUCOSE TRANSPORTER; HEXOKINASE;

ASPIRATION BIOPSY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENIC ACTIVITY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; ECHOGRAPHY; GLUCOSE METABOLISM; HIGH RISK PATIENT; HUMAN; INCIDENTAL FINDING; LABORATORY DIAGNOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; THYROID CANCER; THYROID CARCINOMA; THYROIDECTOMY; TUMOR LOCALIZATION;

BIOPSY, NEEDLE; FLUORODEOXYGLUCOSE F18; HUMANS; INCIDENTAL FINDINGS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; THYROID GLAND; THYROID NEOPLASMS; THYROIDECTOMY; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 48949116126     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2008.02.013     Document Type: Review

References (45)

1. Rohren E.M., Turkington T.G., and Coleman R.E. Clinical applications of PET in oncology. Radiology 231 (2004) 305-332
2. Essner R., Daghighian F., and Giuliano A.E. Advances in FDG PET probes in surgical oncology. Cancer J 8 (2002) 100-108
3. de Geus-Oei L.F., van der Heijden H.F., Visser E.P., et al. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer. J Nucl Med 48 (2007) 1592-1598
4. Choi J.Y., Lee K.S., Kwon O.J., et al. Improved detection of second primary cancer using integrated [18F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging. J Clin Oncol 23 (2005) 7654-7659
5. Kojima S., Zhou B., Teramukai S., et al. Cancer screening of healthy volunteers using whole-body (18)F-FDG-PET scans: the Nishidai clinic study. Eur J Cancer 43 (2007) 1842-1848
6. Ishimori T., Patel P.V., and Wahl R.L. Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med 46 (2005) 752-757
7. Are C., Hsu J.F., Ghossein R.A., et al. Histological aggressiveness of fluorodeoxyglucose positron-emission tomogram (FDG-PET)-detected incidental thyroid carcinomas. Ann Surg Oncol 14 (2007) 3210-3215 Epub 2007 Aug 23
8. Are C., Hsu J.F., Schoder H., et al. FDG-PET detected thyroid incidentalomas: need for further investigation?. Ann Surg Oncol 14 (2007) 239-247
9. Chen Y.-K., Ding H.-J., Chen K.-T., et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for cancer screening in healthy subjects. Anticancer Res 25 (2005) 1421-1426
10. Cohen M.S., Arslan N., Dehdashti F., et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery 130 (2001) 941-946
11. Kang K.W., Kim S.K., Kang H.S., et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 88 (2003) 4100-4104
12. Kim T.Y., Kim W.B., Ryu J.S., et al. 18F-fluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma. Laryngoscope 115 (2005) 1074-1078
13. Wang W., Larson S.M., Tuttle R.M., et al. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 11 (2001) 1169-1175
14. de Geus-Oei L.F., Pieters G.F., Bonenkamp J.J., et al. 18F-FDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results. J Nucl Med 47 (2006) 770-775
15. Mitchell J.C., Grant F., Evenson A.R., et al. Preoperative evaluation of thyroid nodules with 18FDG-PET/CT. Surgery 138 (2005) 1166-1174 discussion 1174-1175
16. Sebastianes F., Cerci J., Zanoni P., et al. Role of 18F-FDG PET in preoperative assessment of cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab (2007) Epub ahead of print
17. Kim J.M., Ryu J.-S., Kim T.Y., et al. 18F-fluorodeoxyglucose positron emission tomography does not predict malignancy in thyroid nodules cytologically diagnosed as follicular neoplasm. J Clin Endocrinol Metab 92 (2007) 1630-1634
18. Brander A., Viikinkoski P., Nickels J., and Kivisaari L. Thyroid gland: US screening in a random adult population. Radiology 181 (1991) 683-687
19. Youserm D.M., Huang T., Loevner L.A., and Langlotz C.P. Clinical and economic impact of incidental thyroid lesions found with CT and MR. Am J Neuroradiol 18 (1997) 1423-1428
20. Mathupala S.P., Ko Y.H., and Pedersen P.L. Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25 (2006) 4777-4786
21. Riedl C., Akhurst T., Larson S., et al. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med 48 (2007) 771-775
22. Shreve P.D., Anzai Y., and Wahl R.L. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 19 (1999) 61-77 quiz 150-151
23. Erdi Y.E., Nehmeh S.A., Mulnix T., et al. PET performance measurements for an LSO-based combined PET/CT scanner using the National Electrical Manufacturers Association NU 2-2001 standard. J Nucl Med 45 (2004) 813-821
24. Kim J.M., Ryu J.-S., Kim T.Y., et al. 18F-fluorodeoxyglucose positron emission tomography does not predict malignancy in thyroid nodules cytologically diagnosed as follicular neoplasm. J Clin Endocrinol Metab 92 (2007) 1630-1634
25. Shaha A.R. Advances in the management of thyroid cancer. Int J Surg 3 (2005) 213-220
26. Feine U., Lietzenmayer R., Hanke J.P., et al. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 37 (1996) 1468-1472
27. Bloom A.D., Adler L.P., and Shuck J.M. Determination of malignancy of thyroid nodules with positron emission tomography. Surgery 114 (1993) 728-734 discussion 734-735
28. Choi J.Y., Lee K.S., Kim H.J., et al. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization. J Nucl Med 47 (2006) 609-615
29. Jeong S.H.-S., Chung M., Baek H.C.-H., et al. Can [18F]-fluorodeoxyglucose standardized uptake values of PET imaging predict pathologic extrathyroid invasion of thyroid papillary microcarcinomas?. Laryngoscope 116 (2006) 2133-2137
30. Karantanis D., Bogsrud T.V., Wiseman G.A., et al. Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland. J Nucl Med 48 (2007) 896-901
31. Bogsrud T.V., Karantanis D., Nathan M.A., et al. The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT. Nucl Med Comm 28 (2007) 373-381
32. Kresnik E., Gallowitsch H.J., Mikosch P., et al. Fluorine-18-fluorodeoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area. Surgery 133 (2003) 294-299
33. Sobrinho-Simões M.A., Nesland J.M., Holm R., et al. Hürthle cell and mitochondrion-rich papillary carcinomas of the thyroid gland: an ultrastructural and immunocytochemical study. Ultrastruct Pathol 8 (1985) 131-142
34. Gianoukakis A.G., Karam M., Cheema A., and Cooper J.A. Autonomous thyroid nodules visualized by positron emission tomography with 18F-fluorodeoxyglucose: a case report and review of the literature. Thyroid 13 (2003) 395-399
35. Yasuda S., Shohtsu A., Ide M., et al. Chronic thyroiditis: diffuse uptake of FDG at PET. Radiology 207 (1998) 775-778
36. Schmid D.T., Kneifel S., Stoeckli S.J., et al. Increased 18F-FDG uptake mimicking thyroid cancer in a patient with Hashimoto's thyroiditis. Eur Radiol 13 (2003) 2119-2121
37. Kurata S., Ishibashi M., Hiromatsu Y., et al. Diffuse and diffuse-plus-focal uptake in the thyroid gland identified by using FDG-PET: prevalence of thyroid cancer and Hashimoto's thyroiditis. Ann Nucl Med 21 (2007) 325-330
38. Johnson T.L., Lloyd R.V., Thompson N.W., et al. Prognostic implications of the tall cell variant of papillary thyroid carcinoma. Am J Surg Pathol 12 (1988) 22-27
39. Andersen P.E., Kinsella J., Loree T.R., et al. Differentiated carcinoma of the thyroid with extrathyroidal extension. Am J Surg 170 (1995) 467-470
40. Bellantone R., Lombardi C.P., Boscherini M., et al. Prognostic factors in differentiated thyroid carcinoma: a multivariate analysis of 234 consecutive patients. J Surg Oncol 68 (1998) 237-241
41. Shaha A. Treatment of thyroid cancer based on risk groups. J Surg Oncol 94 (2006) 683-691
42. Wang W., Larson S.M., Fazzari M., et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 85 (2000) 1107-1113
43. Basu S., and Alavi A. Metastatic malignant melanoma to the thyroid gland detected by FDG-PET imaging. Clin Nucl Med 32 (2007) 388-389
44. Papi G., Fadda G., Corsello S.M., et al. Metastases to the thyroid gland: prevalence, clinicopathological aspects and prognosis: a 10-year experience. Clin Endocrinol 66 (2007) 565-571
45. Nam S.Y., Roh J.-L., Kim J.S., et al. Focal uptake of (18)F-fluorodeoxyglucose by thyroid in patients with nonthyroidal head and neck cancers. Clin Endocrinol 67 (2007) 135-139